🔓 Unlock the full profile of George Lai (Alltrna), including verified contact details, financial insights, and professional associations.
See George Lai Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: geo*****@all******.com
Mobile: 85867*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- George Lai currently serves as the Director of Science and Founder at George Admet LLC since February 2022, emphasizing a strong leadership role in scientific innovation.
- In November 2023, George Lai took on the position of Head of DMPK, Drug Safety, and Clinical Pharmacology at Alltrna, contributing expertise to enhance the company's drug development strategy.
- Previously held the role of Vice President of DMPK and Toxicology at Onsero Therapeutics from June 2022 until December 2023, providing invaluable insight into drug metabolism and pharmacokinetics.
- Served as Vice President of DMPK and Toxicology at Triplet Therapeutics from April 2020 until June 2022, advancing the understanding of pharmacology in therapeutic development.
- Prior to that, served as the Senior Director DMPK at Schrödinger Inc. from May 2019 until May 2020, leading initiatives that integrated computational modeling with pharmacokinetic research.
- From October 2013 to May 2019, George held the position of Senior Director and Head of DMPK Department at Eisai US, where the focus was on integrating DMPK knowledge into the drug development pipeline.
- As a Senior Principal Scientist at Eisai US from November 2008 to October 2013, significant contributions were made towards building a robust framework for drug disposition understanding.
- George completed a pivotal role as Principal Scientist at Boehringer Ingelheim starting March 2000, helping to establish a foundation in conducting DMPK studies.
- Alltrna, founded in 2018, aims to innovate in drug development, and under George Lai's leadership, continues to grow, showcasing a 40% headcount growth over the past two years, signaling an expanding influence in the biotech sector.